Sibel Yilmaz is a partner of the Antitrust and Competition group in the Firm's Brussels-based European & Competition Law Practice. She is a Swedish national living in Brussels and divides her time between the Brussels and Stockholm offices. She joined Baker McKenzie in 2021.
Sibel's experience covers all aspects of competition law and foreign investment within the EU, the Nordics and internationally. She has special sector expertise in healthcare, technology, financial sponsors.
Representative Legal Matters
Examples of merger control matters include:
- Linde on its transformational merger with Praxair.
- Intas/Accord on its GBP 603 million acquisition of Actavis UK.
- EQT and Investor on their SEK 26.5 billion divestment of Gambro to the medical technology company Baxter International Inc.
- Takeda on its disposal of a portfolio of certain respiratory products to AstraZeneca.
- Novartis on its acquisition of GSK’s oncology business (with a deal value of USD 30 billion).
- PAI Partners on is acquisition of market leader Atos Medical.
- NKT on its EUR 712 million acquisition of ABB’s Power cable business.
- Teachers Insurance and Annuity Association (TIAA) in relation to a consortium with Digital Bridge and PSP to acquire Vantage Data Centers.
- Fluxys and Enegas's sale of Swedgas to EON Gas.
- Trelleborg on its SEK 10.9 billion acquisition of ČGS. iance questions.
Examples of external appointments, awards and recognition:
- Appointed as a Non-Governmental Adviser to the Swedish Competition Authority within the merger control working group of the International Competition Network (ICN) since 2016. Included in GCR's 40 under 40 in 2020.
- Sibel is listed in Chamber’s Global rankings as “just really excellent" and "absolutely a tip for the top.“.
- Ranked as the third "Most Highly Regarded" non-partner in Europe in Who's Who Legal (WWL) 2019 'future leaders of international competition practice' with the write up:
"Sibel Yilmaz performed exceptionally in this year's research, with peers describing her as "a brilliant and promising lawyer, who is highly recommended for complex merger work". One source effuses that "she is an exceptional talent", and that "clients love her and she achieves great results for them"."
- Lead associate on the team awarded with the Financial Times's award for Innovative Lawyers in the categories "Competition" and "Outstanding innovation of 2015" for work on the remedy in relation to Novartis acquisition of GSK's Oncology Business.'
- Sweden (2011)
- Brussels (E-List)~Belgium
- Erasmus University Rotterdam (European Master in Law and Economics LL.M. Joint degree Erasmus Universiteit - Rotterdam, Universiteit Gent and Universität Hamburg) (2007)
- Stockholm University (Master of Law - LL.M.) (2006)
- National University of Singapore (Studies in Law - exchange programme) (2006)
- Stockholm University (Studies in Economics) (2005)